| Entry |
|
|---|
| Name |
Amsacrine (USAN/INN);
Amsidyl (TN) |
|---|
| Formula |
C21H19N3O3S
|
|---|
| Exact mass |
393.1147
|
|---|
| Mol weight |
393.46
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Topoisomerase II inhibitor |
|---|
| Target |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX01 Amsacrine
D02321 Amsacrine (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
D02321 Amsacrine
Target-based classification of drugs [BR:br08310]
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP2
D02321 Amsacrine (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 28
1 C8x C 40.9668 -26.7547
2 C8x C 40.9668 -28.1555
3 C8x C 42.1575 -28.8558
4 C8y C 43.4182 -28.1555
5 C8y C 43.4182 -26.7547
6 C8x C 42.1575 -26.0544
7 N5x N 44.6088 -28.8558
8 C8y C 45.7994 -28.1555
9 C8y C 45.7994 -26.7547
10 C8y C 44.6088 -26.0544
11 C8x C 47.0601 -28.8558
12 C8x C 48.2507 -28.1555
13 C8x C 48.2507 -26.7547
14 C8x C 47.0601 -26.0544
15 N1b N 44.6088 -24.6536
16 C8y C 45.7994 -23.9532
17 C8x C 46.9900 -24.6536
18 C8x C 48.2507 -23.9532
19 C8y C 48.2507 -22.5525
20 C8x C 47.0601 -21.8521
21 C8y C 45.7994 -22.5525
22 O2a O 44.6088 -21.8521
23 C1a C 43.4182 -22.5525
24 N1b N 49.4414 -21.8521
25 S4a S 50.8421 -21.8521
26 C1a C 52.2428 -21.8521
27 O3c O 50.8421 -23.2529
28 O3c O 50.8421 -20.4514
BOND 31
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 8 11 1
13 11 12 2
14 12 13 1
15 13 14 2
16 9 14 1
17 10 15 1
18 15 16 1
19 16 17 2
20 17 18 1
21 18 19 2
22 19 20 1
23 20 21 2
24 16 21 1
25 21 22 1
26 22 23 1
27 19 24 1
28 24 25 1
29 25 26 1
30 25 27 2
31 25 28 2
|
|---|
